Transpacific AI biotech makes its Series A debut — putting $86M in the bank
With the rush of AI permeating the biotech industry, another AI player is coming out well-organized and flush with cash. METiS Therapeutics announced this morning that it successfully put $86 million in the bank, thanks to a Series A.
Two investment firms connected to the Chinese government (People’s Insurance Company of China and China Life Insurance Company) led the financing round — and were joined by Sequoia Capital China, 5Y Capital and several other investors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.